Onesource Specialty Pharma profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
Returns
−1.3%−1.3%−0.3%
−0.9%−0.9%−0.2%
0.4%0.4%3.0%
0.6%0.3%1.2%
Margins
23.5%21.4%32.3%
1.8%1.8%13.3%
—720.0%—
−1.2%−6.5%−4.6%
−0.1%−5.2%−1.2%
—−5.2%—
−39.4%−39.4%−1.5%
Additional
92.0%19.8%74.2%
−1.3%−1.3%−0.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,991 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Returns
Return on Common Equity-0.31-1.26-1.26
Return on Assets-0.24-0.94-0.94
Return on Capital Employed2.990.380.38
Return on Invested Capital1.190.290.60
Margins
EBITDA Margin32.2921.4023.51
Operating Margin13.331.771.77
Incremental Operating Margin—720.03—
Pretax Margin-4.64-6.47-1.20
Net Income Margin-1.24-5.19-0.10
Net Income to Common Margin—-5.19—
FCF Margin-1.49-39.43-39.43
Additional
Effective Tax Rate74.2319.7591.95
Sustainable Growth Rate-0.31-1.26-1.26
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.